Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
The worldwide prevalence of non-alcoholic fatty liver disease is around 25%, and that of nonalcoholic steatohepatitis (NASH) ranges from 1.5% to 6.45%. Patients with NASH, especially those with fibrosis, are at higher risk for adverse outcomes such as cirrhosis and liver-related mortality. Although...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Diabetes Association
2020-10-01
|
| Series: | Diabetes & Metabolism Journal |
| Subjects: | |
| Online Access: | http://www.e-dmj.org/upload/pdf/dmj-2020-0115.pdf |